HeartBeam announces availability of shareholder letter
BEAT•Shareholder letter outlines strategic pivot
HeartBeam posted a shareholder letter outlining a strategic pivot toward heart attack detection using its 3D ECG technology.
The plan drops a large commercial build-out for its FDA-cleared arrhythmia product, keeping only limited commercialization to support select customers.
Resources will shift to MI detection clinical validation, algorithm development and the FDA pathway. The company said the MI opportunity is estimated at about $15 billion.
HeartBeam cited completion of 134-patient ALIGN-ACS pilot enrollment; results were accepted for TCT 2026. Its 500-patient HEADSTART-ACS study has passed 75% enrollment.
The company said its 12-lead patch will advance toward FDA clearance, with commercialization targeted through a strategic partner. HeartBeam estimates the patch market at about $2 billion.
